Myriad Genetics Inc (MYGN) financials
Myriad Genetics revenue and earnings by year
Myriad Genetics's revenue was $825 million in the fiscal year to December 31, 2025, down 1.6% from the year before. Net income was -$366 million, -44.4% of revenue. Since the fiscal year to December 31, 2021, revenue has grown 4.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 825 | 838 | 753 | 678 | 691 |
| Revenue growth | -1.6% | 11.2% | 11.0% | -1.8% | — |
| Gross profit | 577 | 585 | 517 | 476 | 493 |
| Gross margin | 69.9% | 69.9% | 68.6% | 70.2% | 71.4% |
| Operating income | -387 | -124 | -257 | -141 | -191 |
| Operating margin | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% |
| Net income | -366 | -127 | -263 | -112 | -27 |
| Net margin | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% |
| Diluted EPS | -$3.95 | -$1.41 | -$3.18 | -$1.39 | -$0.35 |
| Free cash flow | -26 | -38 | -184 | -152 | 1 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open MYGN in Markets.
How Myriad Genetics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Cancer Care Continuum | $114M | 59.8% |
| Prenatal Health | $39.8M | 20.9% |
| Mental Health | $36.8M | 19.3% |
See also: MYGN returns
No forecast, no recommendation. This page describes Myriad Genetics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.